Hosted on MSN

Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN

Alnylam Pharmaceuticals ((ALNY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...
Yahoo Finance

Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg ...

HAMPTON, N.J., Nov. 05, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data from the Company’s Phase 1b study of barzolvolimab in prurigo nodularis (PN).
Business Wire

Mayo Clinic and PN Medical Publish Study that Shows How to Reduce Stress and Anxiety

An 18% reduction in stress was one of the most significant outcomes. ORLANDO, Fla.--(BUSINESS WIRE)--Mayo Clinic released the results of a clinical trial demonstrating the positive outcomes of a ...
The Globe and Mail

Alnylam Pharmaceuticals Launches Promising Phase 3 Study on Nucresiran for hATTR-PN

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alnylam Pharmaceuticals has announced a ...